Participated · Series A · Sep 2023

AbolerIS Pharma is a Belgian biopharmaceutical company focused on immunotherapies for autoimmune and inflammatory diseases. Its lead program is a monoclonal antibody that targets the novel receptor CD45RC with the goal of restoring immune tolerance. The company aims for durable remissions and therapies with fewer side effects compared with current immunosuppressive options. Cofounders Dr. Ignacio Anegon and Dr. Carole Guillonneau and a team of experienced immunology scientists lead the research. The financing announced will be used to accelerate the clinical development of the antibody and advance it toward becoming a potential new treatment standard for conditions such as rheumatoid arthritis.

Participated · Series A · Dec 2020

PathologyWatch operates an end-to-end digital dermatopathology platform that integrates laboratory information systems, scanners, a digital viewer, and EMR reporting to give clinics 24/7 access to digital slides and expert dermatopathologists. The company’s core product streamlines workflows for dermatology clinics and labs, enabling faster diagnoses and broader insurance coverage. PathologyWatch is positioning its platform to improve access and equity in dermatopathology while reducing pathology costs. With the new funding, the company plans further research into skincare diagnostics and AI to enhance its diagnostic capabilities. PathologyWatch is expanding operations nationwide and will add new labs in Texas, Florida, and Arizona to support growing volume. CEO and cofounder Dan Lambert emphasizes the company’s role in digitally transforming dermatopathology and improving patient care. PathologyWatch is a Salt Lake City, UT‑based provider of digital dermatopathology services that offers fully interfaced EMR reporting and around‑the‑clock access to digital slides. The company’s solution gives dermatology clinics, hospitals and laboratories access to top‑tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR. PathologyWatch aims to improve operational efficiency by speeding up workflow and enhance patient outcomes via its expert professional team and partner laboratory services. Led by CEO and co‑founder Dan Lambert, the company has raised over $10M in total capital to date. PathologyWatch plans to use new funding to develop its digital dermatopathology offerings, scale its laboratory system and extend artificial intelligence research across various cancer lines to support larger clients and further technological progress. PathologyWatch builds intuitive, easy‑to‑implement digital dermatopathology solutions that digitize pathology workflows and provide EMR‑integrated reporting and 24/7 access to digital slides. The company offers access to top dermatopathologists and lets clients interpret and bill for cases, with a primary focus on outpatient clinics. PathologyWatch has deployed supervised AI in dermatopathology and reports a live clinical implementation in Australia that can generate full reports. It will use the Series A proceeds to strengthen outreach to dermatology clinics nationwide, including plans to triple its sales force over 12 months, expand marketing, and implement a channel partner strategy. The funding will also support continued development of technology and supervised AI for various cancer lines.

Led · Series A · Dec 2020

BRAINBox Solutions is developing an AI-enabled, multi-modality approach to diagnose and prognose mild traumatic brain injury (concussion) that combines a proprietary panel of blood biomarkers with a digital neurocognitive testing platform to produce a composite TBI injury score. The company is working to deliver both point-of-care instruments and laboratory-based assays that can read the biomarker panel rapidly, and recently validated assay performance in a feasibility study on Prolight Diagnostics' Psyro/Pyros platform using 260 samples from its HeadSMART II pivotal trial. BRAINBox has entered a development agreement with Prolight to adapt that platform and plans to develop advanced hardware and software and acquire pilot instruments. The company intends to deploy its tests in hospital labs as well as clinics, ambulances, emergency departments, nursing homes, and athletic facilities. BRAINBox is led by physician and scientific thought leaders and an experienced clinically focused management team.

Participated · Series B · Nov 2019

SonoMotion is a clinical-stage medical technology company focused on non-invasive, ultrasound-based treatments for kidney stones. Its two main products, Break Wave and Stone Clear, are designed to fragment and clear stones using low-pressure ultrasound while patients remain fully awake, eliminating the need for anesthesia and a surgical suite. Stone Clear secured FDA 510(k) de novo clearance in October 2024, and Break Wave has now finished enrollment in a 64-patient pivotal SOUND trial that will support an upcoming 510(k) submission. Together, the devices share a common platform aimed at offering a complete, first-line solution for stone management in office or clinic settings. Kidney stones affect roughly one in ten Americans and drive more than 750,000 procedures annually, representing a $10 billion U.S. market opportunity. Venture capital–backed SonoMotion continues to advance its regulatory and commercial roadmap, recently bolstered by non-dilutive NIH funding to reach key milestones.

Participated · Series D · Oct 2019

Endotronix develops the Cordella Pulmonary Artery Sensor and the Cordella Heart Failure System to enable remote, pressure-guided management of heart failure patients. The Cordella System is designed to help patients feel better and stay out of the hospital through streamlined care and remote medication titration, providing comprehensive at-home health status and tools to securely collect and share health-related data with providers. The Cordella Sensor integrates pulmonary artery (PA) pressure data into the system to deliver trend-based management and support reimbursement for care delivery activities. The company expanded its Series D financing to $70 million to support the PROACTIVE-HF IDE clinical trial and commercialization of the Cordella System. PROACTIVE-HF is an FDA-approved, prospective, multi-center, randomized, controlled, single-blind pivotal trial planned to enroll over 950 NYHA Class III heart failure patients at up to 60 U.S. sites to evaluate safety and efficacy and to generate data for U.S. market access and reimbursement. Endotronix is also running the open-label SIRONA II CE Mark trial, enrolling 60 patients at up to eight European centers to evaluate safety and efficacy for European market access. Endotronix develops the Cordella Heart Failure System, a remote patient management platform that pairs cloud-based disease management software with an implantable wireless pulmonary artery sensor. The company’s platform collects and transmits daily patient data and hemodynamic insights to clinicians to enable guideline-based therapy and earlier detection of worsening heart failure. Endotronix intends to use the financing to commercialize the Cordella System and to advance clinical development and regulatory approval of the Cordella Pulmonary Artery Sensor through CE Marking and FDA Premarket Approval (PMA). The company is led by CEO Harry Rowland and will expand its board to include Fouad Azzam, Ph.D. The product offering includes outpatient hemodynamic management and aims to extend clinical care into the home. Endotronix is developing the Cordella™ Heart Failure System, an integrated platform that combines a cloud-based disease-management data system with outpatient hemodynamic management and an implantable wireless pulmonary artery sensor for early detection of worsening heart failure. The company focuses on providing comprehensive, reimbursable health management tools for patients with advanced heart failure. Led by CEO Harry Rowland, Endotronix is advancing Cordella through clinical development. Financially, the company received a $12m term loan from Silicon Valley Bank to support the Cordella clinical program. In July 2016 Endotronix completed a $32m Series C that included BioVentures Investors, SV Life Sciences (SVLS), Lumira Capital, Aperture Venture Partners, OSF Ventures, existing investors and a corporate strategic investor. The company is based in Woodridge, Illinois. Endotronix develops digital health medtech solutions that combine a cloud-based patient management system with an implantable wireless pulmonary artery sensor for outpatient hemodynamic management. Led by CEO Harry Rowland, the company's wireless solution integrates daily monitoring of key physiological data with improved communication between patients, caregivers and clinicians to enable earlier detection of worsening heart failure. The technology is intended to reduce heart failure hospitalizations through remote hemodynamic monitoring and care coordination. The company closed a $32m Series C financing to advance its clinical program and commercialization efforts. Endotronix intends to use the funds to conduct its clinical program, commercialize the cloud-based outpatient management system, and complete a safety and feasibility study for its implantable pulmonary artery sensor. The company is based in Woodridge, Illinois. Endotronix is developing wireless, implantable sensor technology licensed from NASA Glenn Research Center that transmits physiological data to a hand-held or wearable device and then to a remote data center. Its implants interact with an external hand-held measurement instrument to enable remote blood-pressure monitoring for congestive heart failure (CHF) patients. The company says the device could help patients and clinicians better monitor and treat heart failure and reduce hospitalizations. Endotronix was formed in early 2007 by Dr. Anthony Nunez and engineer Harry Rowland and began in Peoria before adding a Cleveland office with help from economic development partners. The firm has received a mix of small investments and grants, including a grant from the Lorain County Community College Foundation Innovation Fund. Recent financings include a $250,000 investment from JumpStart Ventures and an angels filing reporting $240,000 raised toward a $375,000 target.